If you have been reading about incretin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Sweden: The nationalist Sweden Democrats entered the Swedish parliament for the first time in the 2010 Swedish general election. France: The far right obtained representatives in the Assembly for the first time since the 1997 election, The National Rally wins two seats in the 2012 legislative election. Germany: The Alternative for Germany (AfD), which was previously unrepresented in the Bundestag, became the third largest party in the Bundestag with 12.6% of the vote in the 2017 German federal election. It was the first time since 1957 that a party to the political right of the CDU/CSU gained seats in the Bundestag. Spain: The far-right Vox party entered Congress for the first time in 2019 Spanish general election. Vox's result signalled the first time since Blas Piñar's election as a deputy for the National Union coalition in 1979 that a far-right party had won seats in the Spanish Parliament after the country's return to democracy as well as the first time that a far-right party would be able to form a parliamentary group of its own in the Congress of Deputies. Portugal:The right-wing/far-right party CHEGA (CH) elected an MP from Lisbon in the 2019 Portuguese legislative election. It was the first time since the return to democracy 45 years that a right-wing/far-right party gained representation in Parliament.
Although it is a relatively immature area of research, it appears that heterotrimeric G-proteins may also take part in non-GPCR signaling. There is evidence for roles as signal transducers in nearly all other types of receptor-mediated signaling, including integrins, receptor tyrosine kinases (RTKs), cytokine receptors (JAK/STATs), as well as modulation of various other "accessory" proteins such as GEFs, guanine-nucleotide dissociation inhibitors (GDIs) and protein phosphatases. There may even be specific proteins of these classes whose primary function is as part of GPCR-independent pathways, termed activators of G-protein signalling (AGS). Both the ubiquity of these interactions and the importance of Gα vs. Gβγ subunits to these processes are still unclear. There are two principal signal transduction pathways involving the G protein-linked receptors: the cAMP signal pathway and the phosphatidylinositol signal pathway.
SNX contains a BAR domain in its C-terminus, which is located between amino acids 256 and 440. Its ability to form coatings in membranes in order to induce their curvature is key in SNX8 participation in tubular structures formation. Furthermore, SNX8 C-terminus contains a threonine in position 452 and a serine in position 456 which can go through post-traductional changes that induces its phosphorylation, resulting in a phosphothreonine and a phosphoserine. Therefore, there are classified as phosphorylation sites. SNX8 has a yeast ortholog protein, the MVP1 encoded by the also homolog gene Mvp1p, which also plays a role by mediating transport of cargo to the vacuolar and lysosomal compartments. For this reason, its investigation can lead to a better understanding of SNX8 functions in human cells.
The protein content of C. vulgaris varies from 42 to 58% of its biomass dry weight. These proteins are considered as having a good nutritional quality compared to the standard profile for human nutrition of the World Health Organization and Food and Agriculture Organization, as the algae synthesizes amino acids. The algae also contains lipids (5–40% of the dry mass), carbohydrates (12–55% dry weight), and pigments including chlorophyll, reaching 1–2 % of the dry weight. Containing dietary minerals and vitamins, C. vulgaris is marketed as a dietary supplement, food additive, or food colorant. Extracted proteins have been investigated for manufacturing of emulsion and foams. It is not widely incorporated in food products due to its dark green color and smell similar to that of fish. As a dietary supplement, it may be sold as capsules, extracts, tablets or powder. Vitamin B12, specifically in the form of methylcobalamin, has been identified in Chlorella vulgaris.
A group at the Nobel Institute for Physics in Stockholm independently discovered the element, producing an isotope later confirmed to be 250Fm (t1/2 = 30 min) by bombarding a 238U target with 16O ions, and published their work in May 1954. Nevertheless, the priority of the Berkeley team was generally recognized, and with it the prerogative to name the new element in honour of Enrico Fermi, the developer of the first artificial self-sustained nuclear reactor. Fermi was still alive when the name was proposed, but had died by the time it became official.
Sources: en.wikipedia.org
=== Pharmacodynamics === In vitro, cannabidiol has low affinity for, and acts as a negative allosteric modulator of the CB1 cannabinoid receptor Cannabidiol may be an antagonist of GPR55, a G protein-coupled receptor and putative non-homologous CB3 cannabinoid receptor shown by in vitro studies to be widely distributed in the brain. Cannabidiol may interact with various neurotransmitters, such as serotonin, dopamine, and GABA. As of 2024, the cellular effects and mechanisms of cannabidiol in vivo are unknown, as research to date has been inconclusive and based on laboratory studies. The anticonvulsant effects provided by cannabidiol (Epidiolex) in people with certain forms of epilepsy do not appear to involve cannabinoid receptors. A possible mechanism for the effects of cannabidiol on seizures is by affecting the neuronal movement of calcium in brain structures involved in the excessive electrical activity of seizures.
== Recalls == In 2018–2019, Teva Pharmaceuticals USA recalled antihypertensive tablets containing valsartan and losartan due to the detection beyond acceptable limit of N-nitrosodiethylamine (NDEA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), respectively, which are probable human carcinogens.
In the 1950s, shipping costs made up 33% of the price of oil transported from the Persian Gulf to the United States, but with the development of supertankers in the 1970s, the cost of shipping dropped to 5% of the price of Persian oil in the US. The share of the shipping cost on the final cost of the delivered commodity was less than 3% in 2010.
The enzyme is an oxidoreductase that uses molecular oxygen in a multi-step oxidation reaction which specifically converts one terminal methyl group of the steroid to its corresponding bile acid. It requires adrenal ferredoxin to transfer electrons from nicotinamide adenine dinucleotide phosphate to the cytochrome P450 active site. The systematic name of this enzyme class is 5beta-cholestane-3alpha,7alpha,12alpha-triol,NADPH:oxygen oxidoreductase (26-hydroxylating). Other names in common use include 5beta-cholestane-3alpha,7alpha,12alpha-triol 26-hydroxylase, 5beta-cholestane-3alpha,7alpha,12alpha-triol hydroxylase, cholestanetriol 26-hydroxylase, sterol 27-hydroxylase, sterol 26-hydroxylase, cholesterol 27-hydroxylase, CYP27A, CYP27A1, and cytochrome P450 27A1'.
== History == Plans for a successor to the original Source engine began following the release of Half-Life 2: Episode Two in 2007. The first engine tech demo was created in 2010 by remaking a map from Left 4 Dead 2. Images of this were leaked onto the internet in early 2014. At the 2014 Game Developers Conference, Valve employee Sergiy Migdalskiy showed off a Source 2 physics debugging tool being used in Left 4 Dead 2. Source 2 was first made available via Steam Workshop tools for Dota 2 in 2014 prior to it being officially announced at the 2015 Game Developers Conference. There, Valve stated their intent for it was to allow for content to be created more efficiently. Valve also stated that it would support the Vulkan graphics API and use a new in-house physics engine called Rubikon, which would replace the need for the third-party Havok tools. Gabe Newell, president and founder of Valve, said that the company were prioritizing the development of their own games before they would release the engine and its software development kit to the public. This was to ensure the highest quality for developers; he added that they were intending to make the engine free to use for game developers as long as the game is published on their Steam service. In June 2015, Valve announced that the entirety of Dota 2 would be ported over to Source 2 in an update called Dota 2 Reborn. Reborn was first released to the public as an opt-in beta update that same month before officially replacing the original client in September 2015, making it the first game to use the engine.
Sources: en.wikipedia.org
(CH2CH2)O + PCl3 → Cl–CH2CH2–OPCl2 2 (CH2CH2)O + PCl3 → (Cl–CH2CH2–O)2PCl 3 (CH2CH2)O + PCl3 → Cl–CH2CH2–O)3P The reaction product of ethylene oxide with acyl chlorides in the presence of sodium iodide is a complex iodoethyl ester:
He held a very wide variety of posts, included Member, Governing Body, Royal Academy of Music, 1967–1979, Director, Central Statistical Office, 1968–1978, BBC Music Advisory Committee, 1971–1983, Visiting Fellow, Nuffield College, Oxford, 1972–1980, Chairman, Royal Opera House, Covent Garden, 1974–1987, Director, N M Rothschild & Sons, 1978–1990 (Vice-chairman, 1978–1984), President, Royal Statistical Society, 1978–1980, Chairman, Economist Intelligence Unit, 1979–1983, Warden of Wadham College, Oxford, 1984–1993, Chancellor, Keele University, 1986–2002, Trustee, London Philharmonic Orchestra, 1988–2000, President, British Association for the Advancement of Science, 1989–1990, Pro-Vice-Chancellor, University of Oxford, 1991–1993, Chairman, British Museum Development Trust, 1993–2003, later Chairman Emeritus, Chancellor, Open University of Israel, 1994–2004 Moss, Celia (1819-1873 and Marion (1821-1901), Anglo-Jewish writers and educators, authors of poetry, prose and fiction, Marion Moss Hartog established the first Jewish women's periodical, the Jewish Sabbath Journal: A Penny and Moral Magazine for the Young, which foundered after it was attacked by the Jewish Chronicle.
=== Meniscus injury === A 2022 review found that in people with meniscus tears, PRP treatment reduced the failure rate of meniscus repair surgery and reduced postoperative pain. However, the review did not find consistent evidence that PRP improved knee function.
Rosanna Jeanne Reardon (born June 8, 1985), known professionally as Rosanna Pansino, is an American YouTuber, businesswoman, and television personality. She is known for hosting her baking series Nerdy Nummies on YouTube (2011–present). She has written two cookbooks and released homeware lines based on the show. She has won a Shorty Award and been nominated for five Streamy Awards for Nerdy Nummies. She was listed first on Forbes' Top Influencers: Food in 2017. Early on in her career, Pansino appeared in minor television roles and the reality series Scream Queens (2010); she later went on to star in the YouTube Premium series Escape the Night (2018–2019) and host the HBO Max series Baketopia (2021). She independently released her debut single "Perfect Together" in 2015.
25 December The Met Office provisionally confirms the highest daily minimum temperature for Christmas Day on record, at 12.4 °C (54.3 °F). However, a white Christmas is recorded in the Scottish Highlands, with snow falling in Tulloch Bridge and Aviemore. Police are investigating a fire at the constituency office of Mike Freer, the MP for North Finchley and Golders Green, which broke out on Christmas Eve. The Food Standards Agency has issued recall notices for five brands of cheese amid concerns they could contain the E.coli bug. King Charles III delivers his second Christmas message in which he emphasises the "universal" values shared between different religions at a time of "increasingly tragic conflict around the world". 26 December Analysts predict that property prices will fall in 2024 but that the cost of rents will rise. A major study published by the Jama Network indicates that a deficiency in Vitamin D, depression and diabetes are major contributing factors to early onset dementia. A yellow weather warning is issued for heavy rain and high winds ahead of the arrival of Storm Gerrit, expected to cause disruption the following day. 27 December The UK government announces that pint-sized bottles of still and sparkling wine will appear on the shelves of British supermarkets. Storm Gerrit: A major incident is declared after a tornado rips through parts of Greater Manchester, knocking down trees and causing significant damage to properties. No injuries are reported.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.